ANI Accumulated Depreciation from 2010 to 2024
| ANIP Stock | USD 57.23 2.16 3.64% |
Accumulated Depreciation | First Reported 2010-12-31 | Previous Quarter -29.4 M | Current Value -30.9 M | Quarterly Volatility 3.4 M |
Check ANI Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among ANI Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 62.8 M, Interest Expense of 28.3 M or Selling General Administrative of 157.9 M, as well as many indicators such as Price To Sales Ratio of 1.94, Dividend Yield of 0.0012 or PTB Ratio of 2.18. ANI financial statements analysis is a perfect complement when working with ANI Pharmaceuticals Valuation or Volatility modules.
ANI | Accumulated Depreciation |
Latest ANI Pharmaceuticals' Accumulated Depreciation Growth Pattern
Below is the plot of the Accumulated Depreciation of ANI Pharmaceuticals over the last few years. Accumulated depreciation is the total amount of depreciation for ANI Pharmaceuticals fixed asset that has been charged to ANI Pharmaceuticals expense since that asset was acquired and made available for ANI Pharmaceuticals use. The accumulated depreciation account is ANI Pharmaceuticals asset account with a credit balance. It is also known as a contra asset account and appears on the balance sheet as a reduction from the gross amount of fixed assets reported by ANI Pharmaceuticals. It is ANI Pharmaceuticals' Accumulated Depreciation historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in ANI Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
| Accumulated Depreciation | 10 Years Trend |
|
Accumulated Depreciation |
| Timeline |
ANI Accumulated Depreciation Regression Statistics
| Arithmetic Mean | (24,569,176) | |
| Coefficient Of Variation | (13.82) | |
| Mean Deviation | 2,581,082 | |
| Median | (22,956,000) | |
| Standard Deviation | 3,396,515 | |
| Sample Variance | 11.5T | |
| Range | 9.8M | |
| R-Value | (0.67) | |
| Mean Square Error | 6.8T | |
| R-Squared | 0.45 | |
| Significance | 0.01 | |
| Slope | (512,095) | |
| Total Sum of Squares | 161.5T |
ANI Accumulated Depreciation History
About ANI Pharmaceuticals Financial Statements
ANI Pharmaceuticals shareholders use historical fundamental indicators, such as Accumulated Depreciation, to determine how well the company is positioned to perform in the future. Although ANI Pharmaceuticals investors may analyze each financial statement separately, they are all interrelated. The changes in ANI Pharmaceuticals' assets and liabilities, for example, are also reflected in the revenues and expenses on on ANI Pharmaceuticals' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Accumulated Depreciation | -29.4 M | -30.9 M |
Pair Trading with ANI Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ANI Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to ANI Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ANI Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ANI Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ANI Pharmaceuticals to buy it.
The correlation of ANI Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ANI Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ANI Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ANI Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for ANI Stock Analysis
When running ANI Pharmaceuticals' price analysis, check to measure ANI Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ANI Pharmaceuticals is operating at the current time. Most of ANI Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of ANI Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ANI Pharmaceuticals' price. Additionally, you may evaluate how the addition of ANI Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.